[go: up one dir, main page]

BRPI0407511A - ésteres de polietilenoglicol ativados - Google Patents

ésteres de polietilenoglicol ativados

Info

Publication number
BRPI0407511A
BRPI0407511A BRPI0407511-0A BRPI0407511A BRPI0407511A BR PI0407511 A BRPI0407511 A BR PI0407511A BR PI0407511 A BRPI0407511 A BR PI0407511A BR PI0407511 A BRPI0407511 A BR PI0407511A
Authority
BR
Brazil
Prior art keywords
polyethylene glycol
esters
oxalate
active
activated
Prior art date
Application number
BRPI0407511-0A
Other languages
English (en)
Inventor
Foe Siong Tjoeng
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0407511A publication Critical patent/BRPI0407511A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

"éSTERES DE POLIETILENOGLICOL ATIVADOS". A presente invenção refere-se à preparação de ésteres carbonatos de polietilenoglicol ativos, úteis para a adição de PEG a peptídeos e proteínas biologicamente ativos e farmaceuticamente úteis. A invenção envolve a utilização de ésteres de carbonato e oxalato ativados, na formação de polietilenoglicol misturado com ésteres de carbonato ativos, que por sua vez reagem com um ligante ou diretamente com um peptídeo ou proteína alvo. Em particular oxalato de N, N<39> dissuccinimidil ou oxalato de 1,1<39> -bis¢6-(trifluormetil) benzotriazoill é usado.
BRPI0407511-0A 2003-02-19 2004-02-13 ésteres de polietilenoglicol ativados BRPI0407511A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44835403P 2003-02-19 2003-02-19
PCT/IB2004/000424 WO2004074345A2 (en) 2003-02-19 2004-02-13 Carbonate esters of polyethylene glycol activated by means of oxalate esters

Publications (1)

Publication Number Publication Date
BRPI0407511A true BRPI0407511A (pt) 2006-02-14

Family

ID=32908577

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407511-0A BRPI0407511A (pt) 2003-02-19 2004-02-13 ésteres de polietilenoglicol ativados

Country Status (9)

Country Link
US (1) US7094872B2 (pt)
EP (1) EP1597299A2 (pt)
JP (1) JP2006517995A (pt)
AR (1) AR043216A1 (pt)
BR (1) BRPI0407511A (pt)
CA (1) CA2515612A1 (pt)
MX (1) MXPA05008785A (pt)
TW (1) TW200426155A (pt)
WO (1) WO2004074345A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045796A2 (en) * 1999-12-22 2001-06-28 Shearwater Corporation Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
ITPD20040159A1 (it) * 2004-06-21 2004-09-21 Univ Degli Studi Trieste Derivati bifunzionali del polietilenglicole loro preparazione e uso.
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
JP2007209543A (ja) * 2006-02-09 2007-08-23 Hidetoshi Tsuchida 表面修飾アルブミンからなる固相膜および酸素吸着膜
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1992020371A1 (en) * 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
CA2515612A1 (en) 2004-09-02
MXPA05008785A (es) 2005-10-18
JP2006517995A (ja) 2006-08-03
WO2004074345A3 (en) 2005-01-20
US20040162388A1 (en) 2004-08-19
WO2004074345A2 (en) 2004-09-02
AR043216A1 (es) 2005-07-20
TW200426155A (en) 2004-12-01
EP1597299A2 (en) 2005-11-23
US7094872B2 (en) 2006-08-22

Similar Documents

Publication Publication Date Title
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
BR0112101A (pt) Interleucina 2 estabilizada
BRPI0515760A (pt) proteìnas de fusão
BR9807098A (pt) Antagonistas de endotelina: n[[2&#39;-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxa zolil)[1,1&#39;-bi-fenil]-2-il]-n,3,3-trimetilbutanamida e n-(4,5-dimetil-3-isoxazolil)-2&#39;-[(3,3-dimetil-2-oxo-1-pirro lidinil) metil]-4&#39;-2-oxazolil)[1,1&#39; -bifenil]-2-sulfonamida e sais dos mesmos
BR0113400A (pt) Método para seleção de peptìdeo
BR0009206A (pt) Isolamento e análise de proteina
WO2001044239A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
BR9915548A (pt) Proteìnas de fusão de interferon-beta e usos
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
AR051512A1 (es) Proteina de fusion que comprende un dominio bh3 de una proteina &#34;solo bh3&#34;
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
BRPI0407511A (pt) ésteres de polietilenoglicol ativados
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ATE356140T1 (de) Gd3 mimetische peptide
EP1339751A4 (en) RECOMBINANT ANTIBODY FRAGMENTS AS AUTO ANTIBODY ANTAGONISTS
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
WO2004056384A3 (en) Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
WO2002055669A3 (en) Regulation of target protein activity through modified proteins
BR9814433A (pt) &#34;beta-lipotropina e usos da mesma&#34;

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01), A61P 5/08 (2006.01), A61P 29